Moderna and Merck’s Melanoma Vaccine Shows Promise in Reducing Cancer Recurrence and Spread

A recent phase 3 clinical trial has unveiled promising results for a personalized mRNA vaccine developed by Moderna and Merck, designed to combat high-risk melanoma. The experimental treatment, known as intismeran, when administered alongside Keytruda (pembrolizumab), has demonstrated significant potential in reducing both the recurrence of melanoma and its spread to other parts of the body.

The trial, which concluded on August 19, achieved its primary goal of recurrence-free survival, indicating that the combination therapy effectively decreases the chances of melanoma returning or resulting in death compared to Keytruda alone. Additionally, it met a crucial secondary endpoint, demonstrating a reduction in the time before the cancer metastasizes, or spreads, to other locations.

While the initial findings are encouraging, detailed results outlining the efficacy and safety of the treatment have yet to be released. Previous phase 2b trials indicated that the combination of intismeran and Keytruda resulted in a 49% lower risk of melanoma recurrence or death and a 59% reduction in the risk of distant metastasis compared to Keytruda alone.

Professor Georgina Long, Medical Director at the Melanoma Institute Australia and lead investigator of the study, expressed optimism regarding these results, calling them a “landmark moment” in the treatment of melanoma. Long noted that this phase 3 study is the first to show that a personalized treatment based on the unique genetic mutations of a patient’s tumor can lead to better outcomes when paired with an established immunotherapy like Keytruda.

### Understanding How the Personalized Vaccine Works

Intismeran represents a novel approach to melanoma treatment, being tailored specifically to the mutations found in each patient’s tumor. The vaccine utilizes messenger RNA (mRNA) technology to instruct the immune system to recognize and attack cancerous cells. By encoding up to 34 unique neoantigens—new proteins that arise from tumor DNA mutations—the vaccine trains T cells to target these specific markers.

Keytruda acts as a checkpoint inhibitor, helping to unleash the immune response against cancer cells. In this combined approach, Keytruda enhances the immune system’s ability to detect tumors, while intismeran provides the necessary guidance to identify and eliminate the cancerous cells.

Although the phase 3 trial continues and intismeran remains investigational and unapproved by the FDA, the companies have indicated plans to present their findings to regulatory authorities and share comprehensive results at upcoming medical conferences.

### Implications for Future Melanoma Treatments

While the results of the phase 3 trial are promising, experts caution that further details are essential to fully understand the treatment’s clinical significance. Dr. Kim Margolin, a medical oncologist at Providence Saint John’s Cancer Institute, emphasized the importance of evaluating the magnitude of benefits provided by the personalized therapy compared to existing immunotherapies.

Moreover, safety remains a critical concern. Immune-based treatments can sometimes lead to adverse effects, as activating the immune system may inadvertently cause it to target healthy tissues. It is crucial to establish whether the addition of a personalized vaccine increases the risk or severity of these immune-related side effects.

The preliminary findings suggest that personalized mRNA therapies could play an integral role in advancing melanoma treatment, though more comprehensive data is necessary to assess their true clinical benefits and potential risks.